

# Poly Medicure Limited

Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate,  
Phase-III, New Delhi - 110 020 (INDIA)  
T: +91-11- 33550700, 47317000  
E: info@polymedicure.com W: polymedicure.com  
CIN: L 40300DL1995PLC066923



Date: 06<sup>th</sup> May, 2025

Scrip Code: - 531768

The Manager,  
BSE Limited,  
Department of Corporate Services,  
Phirozee Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400001.

Scrip Code:- POLYMED

The Manager  
National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1-Block-G  
Bandra Kurla Complex, Bandra(E),  
Mumbai-400051.

**Sub: Submission of Press Release for the Audited Financial Results (Standalone & Consolidated) for Fourth Quarter and Financial Year ended on March 31, 2025**

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release with respect to Audited Financial Results (Standalone & Consolidated) for Fourth Quarter and Financial Year ended on March 31, 2025.

Request you to take the same on records.

Thanking You,

Yours Sincerely

For Poly Medicure Limited

Avinash Chandra  
Company Secretary  
M. No. A32270



## Poly Medicare Limited Reports Fourth Quarter & FY 2025 Results

**Quarterly and FY 25 Consolidated Revenue growth of 17% and 21% respectively on a YoY basis**

**FY 25 Consolidated EBITDA growth of 27% on a YoY basis, Q4 Core EBITDA margin 27.1%**

**Consolidated Quarterly and yearly PAT Growth of 34% and 31% respectively on a YoY basis; Q4 PAT margin of 20.8%**

**New Delhi, May 06<sup>th</sup>, 2025: Poly Medicare Ltd. (NSE: POLYMED | BSE: 531768),** India's leading Medical Device company with a dominant position in medical consumables market, today announced its audited consolidated and standalone financial results for the quarter and year ended on March 31st, 2025.

### Key Financial Summary:

Consolidated Rs. Crores	Q4 2025	Q4 2024	YoY Growth (%)	FY 2025	FY 2024	YoY Growth (%)
Consolidated Revenue from Operations	440.8	378.1	16.6%	1669.8	1375.8	21.4%
EBITDA	119.5	96.5	23.8%	452.8	357.7	26.6%
EBITDA Margin	27.1%	25.5%	+160BPS	27.1%	26.0%	+113BPS
Profit after Tax	91.8	68.4	34.3%	338.6	258.3	31.1%
PAT Margin	20.8%	18.1%	+270BPS	20.3%	18.8%	+150BPS
EPS - Basic	8.9	7.1	25.2%	34.1	26.9	26.8%

### Key Financial Highlights:

- Revenue from operations increased by 17% in Q4 2025 compared to Q4 2024; FY2025 revenue growth stood at 21%.
- Export revenue for FY2025 increased by 24% YoY, driven by continued strong performance in key international markets. Geopolitical tensions and tariff war creating short term demand uncertainty in certain export markets.
- The domestic quarterly and yearly revenue growth was 24% and 19% respectively on a YoY basis, domestic revenue growth has shown strong traction as the year progressed.
- Renal division continues to gain market share in the domestic market with revenue growth of 69% and 60% in Q4 and FY2025 period respectively.
- EBITDA grew by 24% in Q4 2025 on a YoY basis, reflecting our strong earnings capability from core operations. The EBITDA margins improved by 160BPS to 27% in Q4 2025.
- Profit After Tax (PAT) increased by 34% in Q4 2025 compared to Q4 2024, ; PAT margin expanded by almost 270BPS to 21% in Q4 2025.
- The balance sheet position remains strong with liquidity position of Rs. 1220crs as at March 25
- Adjusted RoCE\* was 23.4% for FY 25 as compared to 23% in the corresponding previous financial year
- Incurred a CAPEX of Rs. 325crs in FY 25 reflecting our commitment to create adequate infrastructure to capture future growth opportunities in the sector.

\* Excludes the impact of amount raised through QIP in August 2024, EBIT has been computed after excluding the treasury income generated from the QIP Funds; calculated on the basis of Standalone Financial Statement

**Commenting on the results for the quarter, Mr. Himanshu Baid, Managing Director, Poly Medicure Limited stated:**

We are extremely pleased with our continued growth in the business in the Q4 and FY2025. Our margins continue to expand at higher scale of operations and that gives us immense confidence to keep investing capital to create additional manufacturing capacities.

FY 2025 has been a transformative year for Polymed as we commercialised two new divisions, Cardiology and Critical Care. Our renal division continues to grow from strength to strength while the core infusion therapy consolidates its leadership position in clinically driven segments.

The current ongoing geopolitical condition as well as uncertainty created due to US imposed tariffs may create short term pressure on demand in certain export markets. We believe that India MedTech sector is well-positioned to benefit from this situation on a longer term basis as global customers look to create alternate supply chains.

Our investment in 3 new plants is going on strongly, which we believe positions us very strongly to achieve the significant growth opportunities that lie in front of us.

**About Poly Medicure Limited:**

Poly Medicure Ltd is a leading medical device manufacturer and exporter from India, with its products sold in over 125 countries, making a significant global impact on healthcare. With a robust portfolio of over 200 medical devices and more than 300 patents, Polymed offers a comprehensive range of medical devices across 12 medical therapies, including infusion therapy, vascular access, dialysis and renal care, critical care, cardiology, oncology, transfusion, diagnostics, gastroenterology, anaesthesia and respiratory care, urology, and surgery and wound management. Supported by 12 state-of-the-art manufacturing facilities across 4 countries, Polymed has the capacity to produce over 1.5 billion medical devices annually, meeting the ever-growing global demand. The company's diverse product offering ensures it addresses a wide range of medical needs worldwide.

**Disclaimer:**

This press release contains forward-looking statements based on current expectations, assumptions, estimates, and projections about Poly Medicure Limited and its industry. These forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to differ materially include, but are not limited to, changes in economic conditions, competitive landscape, regulatory developments, and other risks detailed in the company's filings with regulatory authorities. Poly Medicure Limited undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

The financial information provided in this press release is unaudited and subject to change. Investors are advised to review the company's audited financial statements and other disclosures available on the company's website and through regulatory filings.

**For more details, please contact:****Rahul Gautam**

Investor Relations  
investorcare@polymedicure.com

**Hitesh Sardana,**

Corporate Communication  
hitesh.sardana@polymedicure.com